Asthma and COPD Medicines - American Lung Association SMART (Single Maintenance and Reliever Therapy) or MART (Maintenance and Reliever Therapy) are a next-generation asthma treatment containing an ICS (inhaled corticosteroid) with formoterol (long-acting beta agonist) combined into one inhaler
LABA LAMA as First-Line Therapy for COPD: A Summary of the Evidence and . . . In the following sections, we review the role of LABA LAMA within the COPD treatment paradigm by describing the evidence for the relative effectiveness of available LABA LAMA combinations versus long-acting bronchodilator monotherapy, LABA ICS and LABA LAMA ICS
Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled . . . - CHEST Recent treatment guidelines for COPD have replaced the long-acting beta 2 -agonist (LABA) and inhaled corticosteroid (ICS) combination with single-inhaler triple therapy that adds a long-acting muscarinic antagonist (LAMA)
Inhaled triple therapy - NCBI Bookshelf - National Center for . . . This review aimed to evaluate the effectiveness of triple therapy, either delivered as a combination of inhalers, or as one single inhaler, in managing the symptoms of patients with severe COPD in comparison to the dual therapy combinations of LAMA+LABA and LABA+ICS
Triple therapy (ICS LABA LAMA) in COPD: time for a reappraisal Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting β 2 -agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have become available for patients with COPD
Pharmacologic Treatment of COPD: Disparities Between Evidence and . . . Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and the third cause of death worldwide [Citation 1] Its pharmacologic treatment involves long-acting beta 2-agonist (LABA) and muscarinic antagonist (LAMA) bronchodilators, and anti-inflammatory inhaled corticosteroids (ICS), now formulated in single-inhaler dual and triple combinations [Citation 2]